Edition:
India

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

4.07USD
11 Dec 2017
Change (% chg)

$-0.03 (-0.73%)
Prev Close
$4.10
Open
$4.11
Day's High
$4.18
Day's Low
$4.05
Volume
22,865
Avg. Vol
69,031
52-wk High
$9.40
52-wk Low
$1.84

Select another date:

Thu, Nov 2 2017

BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates

BRIEF-EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

* EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

BRIEF-Conatus Pharmaceuticals files for mixed shelf of upto $100 mln

* Conatus Pharmaceuticals Inc files for mixed shelf of upto $100 million - SEC filing Source text: (http://bit.ly/2x8wope) Further company coverage:

BRIEF-Conatus announces completion of enrollment

* Conatus announces completion of enrollment in encore-NF phase 2B clinical trial of emricasan in patients with NASH fibrosis Source text for Eikon: Further company coverage:

BRIEF-Conatus announces effectiveness of exclusive license with Novartis

* Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms

BRIEF-FDA grants Conatus orphan drug designation for idn-7314 for the treatment of PSC

* FDA grants conatus orphan drug designation for idn-7314 for the treatment of PSC Source text for Eikon: Further company coverage:

Select another date: